preflucel 15 mikrogram injektionsvæske, suspension, fyldt injektionssprøjte
nanotherapeutics bohumil s.r.o. - influenzavirus a/california/7/2009 (h1n1)v-lign. stamme, inaktiverede split virioner, influenzavirus a/perth/16/2009 (h3n2) lignende stamme (a/victoria/210/2009 nymc x-187 reassortant), influenzavirus b/brisbane/60/2008, split virioner, inaktiveret - injektionsvæske, suspension, fyldt injektionssprøjte - 15 mikrogram
vepacel
ology bioservices ireland ltd - influenzavirus (hel virion, inaktiveret), der indeholder antigen af: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenzavacciner - aktiv immunisering mod h5n1-subtype af influenza a-virus. denne angivelse er baseret på immunogenicitet data fra forsøgspersoner i alderen fra 6 måneder og frem efter administration af to doser af vaccinen tilberedes med h5n1 subtype stammer. vepacel bør anvendes i overensstemmelse med officielle retningslinjer.
albumin "baxalta" 200 g/l infusionsvæske, opløsning
baxalta innovations gmbh - albumin, human - infusionsvæske, opløsning - 200 g/l
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicinhydrochlorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiske midler - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
celvapan
nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vacciner - profylakse af influenza forårsaget af a (h1n1) v 2009 virus. celvapan bør anvendes i overensstemmelse med officielle retningslinjer.
accusol 35 hæmodiafiltreringsvæske, opløsning
nikkiso belgium - calciumchloriddihydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - hæmodiafiltreringsvæske, opløsning
accusol 35 kalium 2 mmol/l 2 mmol/l hæmodiafiltreringsvæske, opløsning
nikkiso belgium - calciumchloriddihydrat, glucose, vandfri, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - hæmodiafiltreringsvæske, opløsning - 2 mmol/l
accusol 35 kalium 4 mmol/l 4 mmol/l hæmodiafiltreringsvæske, opløsning
nikkiso belgium - calciumchloriddihydrat, glucose, vandfri, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - hæmodiafiltreringsvæske, opløsning - 4 mmol/l
prothromplex 600 ie pulver og solvens til injektionsvæske, opløsning
baxalta innovations gmbh - koagulationsfaktor ii, humant, koagulationsfaktor ix, humant, koagulationsfaktor vii, humant, koagulationsfaktor x, humant, protein c, human - pulver og solvens til injektionsvæske, opløsning - 600 ie
subcuvia 160 mg/ml injektionsvæske, opløsning
baxalta innovations gmbh - normalt immunglobulin, humant - injektionsvæske, opløsning - 160 mg/ml